ArticleClinical microbiology newsletter2021
Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19.
Article in Clinical microbiology newsletter, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.The Journal of clinical investigation · 2021Trial
- Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study.PLoS medicine · 2021Trial
- Early Convalescent Plasma for High-Risk Outpatients with Covid-19.The New England journal of medicine · 2021Trial
- Intelligent Patient Management in Viral Diseases: An Integrated Regression Model and Multi-Criteria Decision-Making Approach to Convalescent Plasma Transfusion.Healthcare (Basel, Switzerland) · 2025Article
- Cure of experimentalmBio · 2025Article
- Evidence for the Efficacy of COVID-19 Convalescent Plasma.Current topics in microbiology and immunology · 2025Review
- Convalescent Plasma and the US Expanded Access Program: A Personal Narrative.Current topics in microbiology and immunology · 2025Review
- The Importance of Antibody Titer Determination to the Effective Use of Convalescent Plasma.Current topics in microbiology and immunology · 2025Review
- COVID-19 clinical presentation, management, and epidemiology: a concise compendium.Frontiers in public health · 2025Review
- Review
- Lack of memory recall in human CD4 T cells elicited by the first encounter with SARS-CoV-2.iScience · 2024Article
- Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review.Life (Basel, Switzerland) · 2024Review
- Emerging Pathogen Threats in Transfusion Medicine: Improving Safety and Confidence with Pathogen Reduction Technologies.Pathogens (Basel, Switzerland) · 2023Review
- Exercise and Experiments of Nature.Comprehensive Physiology · 2023Article
- Article
- Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Article
- Convalescent plasma to deliver therapeutic antibodies against COVID-19.Trends in molecular medicine · 2022Article
- Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants.JCI insight · 2022Article
- Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience.Life (Basel, Switzerland) · 2022Article
- Coagulation profile of human COVID-19 convalescent plasma.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Convalescent plasma has emerged as a promising therapeutic agent for patients with coronavirus disease 2019 (COVID-19), has received emergency use authorization, and is being widely used during the COVID-19 pandemic. Passive antibody therapy via plasma or serum has been successfully used to treat infectious diseases for more than a century. Passive antibody administration is based on the presumption that convalescent plasma or serum contains therapeutic antibodies that can be passively transferred to the plasma recipient. There are numerous examples in which convalescent plasma has been used successfully as post-exposure prophylaxis and treatment of infectious diseases, including previous coronavirus outbreaks. In the context of the COVID-19 pandemic, convalescent plasma was demonstrated to be safe and potentially effective among patients infected with COVID-19. This review provides an overview of the historical uses of convalescent plasma therapy, summarizes current evidence for convalescent plasma use for COVID-19, and highlights future antibody therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.